Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCB-2019
- Development stage
- Phase 3
- Lead developer
- Clover Biopharmaceuticals
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SCB-2019 is a recombinant trimeric spike (S) protein subunit vaccine developed for the prevention of COVID-19. The vaccine contains a stabilized, pre-fusion form of the SARS-CoV-2 spike protein produced in Chinese hamster ovary (CHO) cells and formulated with adjuvants such as CpG 1018 (a TLR9 agonist from Dynavax Technologies) and aluminum hydroxide or AS03 (from GSK). The S-protein is fused with Trimer-Tag to preserve its native trimeric structure, enhancing immunogenicity. SCB-2019 induces protective immunity by stimulating neutralizing antibody responses against SARS-CoV-2, including various variants. Clinical trials have shown efficacy against symptomatic and severe COVID-19 cases. The vaccine is administered intramuscularly in two doses four weeks apart and remains stable under standard refrigeration[1][2][3][4][5][6].
- Other names
- S-TrimerClover COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SCB-2019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCB-2019.